Table 1.

Patient and tumour characteristics at the time of CDKi treatment initiation

	Total (n=365)
Age* (years)
Median (min, max)	60.9 (34.4,93.3)
	N (%)
Age* (years)
<75	319 (88.1)
≥75	43 (11.9)
Menopausal status*
Postmenopausal	290 (80.6)
Premenopausal	70 (19.4)
Tumour location*
Left	186 (51.4)
Right	170 (47.0)
Bilateral	6 (1.7)
ER status*†
Negative	2 (0.55)
Positive	361 (99.4)
PR status*†
Negative	78 (21.7)
Positive	282 (78.3)
Stage at initial diagnosis*
I	45 (13.0)
II	116 (33.5)
III	86 (24.9)
IV	99 (28.6)
CDKi
Palbociclib	301 (82.5)
Ribociclib	64 (17.5)

*Data not available for all subjects. Missing values: age=3, menopausal status=5, tumour location=3, ER status=2, PgR status=5, stage=19.

†Hormone receptor status examined at most recent histological sample

CDKi, cyclin-dependent kinase inhibitor; ER, oestrogen receptor; N, number; PR, progesterone receptor.